Immunodeficient mice have been used extensively as a means to grow both normal and transformed cells and/or tissues of various lineages in an in vivo environment. These in vivo models are helpful for many areas of cancer research. To this end, UCLA has established an immunodeficient mouse core laboratory which breeds and houses sever combined immunodeficient (SCID) mice, and provides housing for nude (athymic) mice for biomedical research. In this facility, investigators can introduce normal or transformed tissues of human or murine origin into immunodeficient mice that will not reject the implanted tissues. Consequently, experiments can be performed which provide insights into how these cells behave in vivo and address experimental therapeutic protocols. The nude/SCID mouse core will help the investigators in all 5 components of this Program Project through the following specific aims: 1. To provide SCID mice at reduced costs to Investigators in the Program Project. 2. To maintain an appropriate working laboratory for biosafety level 2 (BSL-2) animal experiments related to this Program Project, which will include appropriate housing for nude and SCID mice, surgical equipment and supplies. 3. To provide animal maintenance and technical assistance for in vivo experiments related to this program project. 4. To provide expertise/consultation on animal experimentation and surgical techniques required for the proposed studies. This facility provides a clean barrier facility with appropriate equipment and supplies at minimal expense to investigators. In addition, animals are maintained and inspected by Core personnel. These personnel are also available to assist in animal manipulations. In vivo studies are important in all components of this application, thus this Core will provide a valuable service to this Program Project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA032737-18A2
Application #
6657491
Study Section
Project Start
2002-09-16
Project End
2003-06-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
18
Fiscal Year
2002
Total Cost
$181,487
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
O'Brien, Neil A; McDonald, Karen; Tong, Luo et al. (2014) Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. Clin Cancer Res 20:3507-20
Short, John D; Dere, Ruhee; Houston, Kevin D et al. (2010) AMPK-mediated phosphorylation of murine p27 at T197 promotes binding of 14-3-3 proteins and increases p27 stability. Mol Carcinog 49:429-39
Lu, Jie; Chan, Lai; Fiji, Hannah D G et al. (2009) In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. Mol Cancer Ther 8:1218-26
Klichko, Yaroslav; Liong, Monty; Choi, Eunshil et al. (2009) Mesostructured Silica for Optical Functionality, Nanomachines, and Drug Delivery. J Am Ceram Soc 92:s2-s10
Short, John D; Houston, Kevin D; Dere, Ruhee et al. (2008) AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. Cancer Res 68:6496-506
Lu, Jie; Choi, Eunshil; Tamanoi, Fuyuhiko et al. (2008) Light-activated nanoimpeller-controlled drug release in cancer cells. Small 4:421-6
Liong, Monty; Lu, Jie; Kovochich, Michael et al. (2008) Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2:889-96
Watanabe, Masaru; Fiji, Hannah D G; Guo, Lea et al. (2008) Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. J Biol Chem 283:9571-9
Lu, Jie; Liong, Monty; Sherman, Sean et al. (2007) Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer Cells. Nanobiotechnology 3:89-95
Lu, Jie; Liong, Monty; Zink, Jeffrey I et al. (2007) Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 3:1341-6

Showing the most recent 10 out of 213 publications